Vanda Pharmaceuticals, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 356
Rang # Quantité totale PI 3 587
Note d'activité PI 3,1/5.0    231
Rang # Activité PI 3 024
Symbole boursier
ISIN US9216591084
Capitalisation 314M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

167 45
48 12
73 6
5
 
Dernier brevet 2024 - Tasimelteon for use in the treat...
Premier brevet 1979 - Shoe tree
Dernière marque 2025 - KIMOLOS
Première marque 2006 - VANDA

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharm...
2024 Invention Method of treatment with tradipitant. Methods of treating an individual experiencing or at risk ...
Invention Treatment of circadian rhythm disorders. Embodiments of the invention relate to the use of a mel...
Invention Multiple myeloma treatment. The invention relates generally to the treatment of multiple myeloma...
Invention Method of treatment. One embodiment of the invention provides a method for administering tasimel...
Invention Highly purified pharmaceutical grade tasimelteon. A process for preparing a batch of highly puri...
Invention Tasimelteon for use in the treatment of delayed sleep-wake phase disorder. The invention relates ...
Invention Melatonin agonist treatment. Melatonin Agonist, MA-1, is administered at effective doses.
Invention Method of treatment with iloperidone. Described herein is an improved method of treatment with il...
Invention Method of treatment. Embodiments of the invention relate generally to the treatment of schizophr...
Invention Method of treatment. Embodiments of the invention relate to the treatment of sleep disturbances ...
Invention Tasimelteon for use in the treatment of patients with optic nerve hypoplasia in order to improve ...
Invention Antisense oligonucleotide (aso) gene inhibition and treatment. Embodiments of the invention relat...
Invention Use of tradipitant in motion sickness. Disclosed herein is a method of treating or preventing mo...
Invention Depot administration of iloperidone. Methods of preparing and administering an injectable depot ...
Invention Sleep or post-sleep performance. The invention relates generally to improving sleep, post-sleep ...
Invention Treatment of disorders with tasimelteon. Tasimelteon improves sleep in individuals experiencing ...
Invention Tasimelteon for treating circadian rhythm sleep disorder. The invention provides methods of impro...
P/S Insurance services, namely, insurance eligibility review and verification and consultation in the...
Invention Improved use of tradipitant in motion sickness. Disclosed herein is an improved method of treati...
Invention Treatment of circadian rhythm disorders. Embodiments of the invention relate to the use of a mela...
P/S Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical p...
2023 Invention Methods of treatment with tradipitant. Disclosed herein are methods of administration of tradipit...
Invention Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia. Embodiments of th...
Invention Treatment of acute anxiety with an alpha-7 nicotinic acetylcholine receptor modulator. Disclosed...
Invention Iloperidone metabolite for use in the treatment of psychiatric disorders. R-P88 is used for the ...
P/S Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and...
Invention Method of treatment with tradipitant. Disclosed herein is a method of treatment of gastric motil...
Invention Method of treatment with tradipitant. Disclosed herein is a method of treatment of an individual...
Invention Highly purified pharmaceutical grade tasimelteon. A process for preparing a batch of highly purif...
Invention Liquid tasimelteon formulations and methods of use thereof. Liquid suspensions of tasimelteon an...
Invention Pharmaceutical combination comprising ponesimod. The present invention relates to a pharmaceutic...
Invention Methods for the administration of iloperidone. The present invention relates to methods for the ...
Invention Pharmaceutical combination comprising a selective s1p1 receptor agonist. The present invention r...
Invention Cancer treatment. The invention relates generally to the treatment of cancer. One embodiment of ...
Invention Treatment of parkinson's disease and parkinson's disease psychosis. The invention relates general...
Invention Trichostatin a (tsa) sensitivity in the treatment of tumors. Embodiments of the invention relate ...
Invention Method of treatment of schizophrenia. The invention relates generally to improvements in the tre...
P/S Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations fo...
Invention Methods of slowing an increase in brain ventricular volume. The disclosure relates to methods of...
2022 Invention Prediction of severity of covid-19 and methods of treatment. The invention relates generally to ...
Invention Prediction of severity of covid-19 and methods of treatment. The invention relates generally to c...
Invention Methods for treating multiple sclerosis. The disclosure relates to methods of preserving myelina...
Invention Treatment of lower respiratory tract infection with tradipitant. Disclosed herein is a method of...
Invention Treatment or prevention of sars-cov-2 infection using (s)-crizotinib. Embodiments of the inventi...
Invention Antisense oligonucleotide (aso) gene inhibition and treatment. Embodiments of the invention rela...
P/S Pharmaceutical preparations containing tasimelteon for use in the treatment of Autism Spectrum Di...
P/S Pharmaceutical and medicinal preparations for the treatment, prevention, or amelioration of sympt...
P/S Pharmaceutical preparations for the treatment of multiple sclerosis Providing information related...
2021 Invention Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist. D...
Invention Methods of treating pde iv-mediated diseases or conditions. The disclosure provides methods and ...
P/S Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for ...
P/S Providing information in the field of multiple sclerosis
Invention Identification and use of compounds in the treatment or prevention of severe acute respiratory sy...
P/S Pharmaceutical preparations for the treatment of multiple sclerosis
Invention Improved treatment of atopic dermatitis with tradipitant. The disclosure relates generally to im...
2020 P/S Providing information in the field of treatment and management of multiple sclerosis
P/S Pharmaceutical preparations, in liquid form and containing tasimelteon, for use in the treatment ...
P/S Pharmaceutical preparations, containing tasimelteon, for use in the treatment of Smith-Magenis Sy...
2019 P/S Pharmaceutical preparations for the treatment of multiple sclerosis
P/S Pharmaceutical preparations, containing tasimelteon, for use in the treatment of circadian rhythm...
2016 P/S Pharmaceutical preparations and substances for use in the treatment of the central nervous syste...
P/S Pharmaceutical preparations and substances for use in the treatment of schizophrenia; pharmaceuti...
P/S Pharmaceutical preparations; pharmaceutical preparations and substances for use in the treatment ...
P/S Business administration connected with the provision of patient access to pharmaceuticals; busine...
2015 P/S pharmaceutical preparations and substances for use in the treatment of the central nervous system...
2014 P/S Pharmaceutical preparations for use in the treatment of diseases and disorders of the central ne...
P/S Pharmaceutical preparations for use in the treatment of diseases and disorders of the central ner...
P/S Pharmaceutical preparations, containing tasimelteon, for use in the treatment of diseases and dis...